Newbury Pharmaceuticals signs 10-year exclusivity deal for 40-product hospital portfolio in Iraq
Bitget2026/09/28 12:01- Newbury Pharmaceuticals entered a 10-year exclusivity agreement with a Chinese drug manufacturer covering a 40-product hospital portfolio in Iraq.
- Deal grants exclusive rights to register, market, sell products in Iraq under Newbury labels, targeting acute care and injectable medicines.
- Portfolio centers on anti-infectives, pain and surgical-support drugs, gastroenterology injectables, supportive care products for hospital tenders, private channels.
- Newbury applied for an Iraqi import license that could enable limited early supply ahead of full marketing authorizations.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The new Roadster is about to debut: Is "Tesla can fly" just hype or reality?
BUZZ - Super Micro appoints Mark Long as Chief Financial Officer; shares fall
The US stock market opened mixed, with the Nasdaq down 331 points.
"Super bull" Yardeni lowers S&P year-end target: Earnings are not the problem, valuation is
Yardeni Research has lowered its year-end S&P 500 target to 7,900 points and reduced its valuation target to 18.6 times, mainly due to risk-off sentiment suppressing valuations rather than deteriorating earnings. Despite facing risk aversion and policy risks, Yardeni remains optimistic about corporate earnings and the medium-to-long-term economy, viewing pullbacks as buying opportunities.
Crypto prices
More
